{"generic":"Quinupristin\/Dalfopristin","drugs":["Quinupristin\/Dalfopristin","Synercid"],"mono":[{"id":"jtrgs0","title":"Generic Names","mono":"Quinupristin\/Dalfopristin"},{"id":"jtrgs1","title":"Dosing and Indications","sub":[{"id":"jtrgs1b4","title":"Adult Dosing","mono":"<ul><li><b>Bacteremia associated with intravascular line, due to ampicillin- and vancomycin-resistant Enterococcus faecium:<\/b> 7.5 mg\/kg IV every 8 hours<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue, Complicated:<\/b> 7.5 mg\/kg IV every 12 hours for a minimum of 7 days<\/li><li><b>Infective endocarditis, due to vancomycin-resistant Enterococcus faecium:<\/b> 7.5 mg\/kg IV every 8 hours for a minimum of 8 weeks<\/li><\/ul>"},{"id":"jtrgs1b5","title":"Pediatric Dosing","mono":"<ul><li>safety and effectiveness have not been established for pediatric patients less than 16 years of age<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue, Complicated:<\/b> (12 years and older) 7.5 mg\/kg IV every 12 hours for a minimum of 7 days<\/li><li><b>Infective endocarditis, due to vancomycin-resistant Enterococcus faecium:<\/b> 7.5 mg\/kg IV every 8 hours for a minimum of 8 weeks<\/li><\/ul>"},{"id":"jtrgs1b6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> no dosage adjustment necessary<\/li><li><b>hepatic impairment:<\/b> dose reduction may be needed; no specific dose adjustment recommendations available<\/li><li><b>geriatric:<\/b> no dosage adjustment necessary<\/li><li><b>peritoneal dialysis:<\/b> no dosage adjustment necessary<\/li><\/ul>"},{"id":"jtrgs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Infection of skin AND\/OR subcutaneous tissue, Complicated<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Bacteremia associated with intravascular line, due to ampicillin- and vancomycin-resistant Enterococcus faecium<\/li><li>Infective endocarditis, due to vancomycin-resistant Enterococcus faecium<\/li><li>Methicillin resistant Staphylococcus aureus infection<\/li><li>Vancomycin-resistant Enterococcus faecium infection<\/li><\/ul>"}]},{"id":"jtrgs2","title":"Black Box Warning","mono":"<b>Intravenous (Powder for Solution)<\/b><br\/>Quinupristin\/dalfopristin has been approved for marketing in the United States for vancomycin-resistant Enterococcus faecium (VREF) bacteremia under FDA's accelerated approval regulations that allow marketing of products for use in life-threatening conditions when other therapies are not available. Approval of this indication is based upon quinupristin\/dalfopristin's ability to clear VREF from the bloodstream, with clearance of bacteremia considered to be a surrogate endpoint. There are no results from well-controlled clinical studies that confirm the validity of this surrogate marker.<br\/>"},{"id":"jtrgs3","title":"Contraindications\/Warnings","sub":[{"id":"jtrgs3b9","title":"Contraindications","mono":"hypersensitivity to quinupristin\/dalfopristin or to other streptogramins (eg, pristinamycin, virginiamycin) <br\/>"},{"id":"jtrgs3b10","title":"Precautions","mono":"concomitant use with agents metabolized by the CYP3A4 pathway that may prolong the QTc interval; use should be avoided <br\/>"},{"id":"jtrgs3b11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"jtrgs3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"jtrgs4","title":"Drug Interactions","sub":{"1":{"id":"jtrgs4b14","title":"Major","mono":"<ul><li>Astemizole (probable)<\/li><li>Atorvastatin (probable)<\/li><li>Cerivastatin (probable)<\/li><li>Fluvastatin (probable)<\/li><li>Haloperidol (probable)<\/li><li>Lovastatin (probable)<\/li><li>Pravastatin (probable)<\/li><li>Simvastatin (probable)<\/li><li>Vinblastine (theoretical)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><li>Vinorelbine (theoretical)<\/li><\/ul>"},"2":{"id":"jtrgs4b15","title":"Moderate","mono":"<ul><li>Amlodipine (probable)<\/li><li>Carbamazepine (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Delavirdine (probable)<\/li><li>Diazepam (probable)<\/li><li>Diltiazem (probable)<\/li><li>Disopyramide (probable)<\/li><li>Docetaxel (probable)<\/li><li>Felodipine (probable)<\/li><li>Indinavir (probable)<\/li><li>Isradipine (probable)<\/li><li>Lacidipine (probable)<\/li><li>Lidocaine (probable)<\/li><li>Manidipine (probable)<\/li><li>Methylprednisolone (probable)<\/li><li>Midazolam (probable)<\/li><li>Nevirapine (probable)<\/li><li>Nicardipine (probable)<\/li><li>Nifedipine (probable)<\/li><li>Nilvadipine (probable)<\/li><li>Nimodipine (probable)<\/li><li>Nisoldipine (probable)<\/li><li>Nitrendipine (probable)<\/li><li>Paclitaxel (probable)<\/li><li>Quinidine (probable)<\/li><li>Ritonavir (probable)<\/li><li>Tacrolimus (probable)<\/li><li>Verapamil (probable)<\/li><\/ul>"}}},{"id":"jtrgs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site edema (17.3%), Injection site inflammation (42%), Injection site pain (40%), Injection site reaction (13.4%), Rash (2.5%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (2.7%), Nausea (4.6%), Vomiting (2.7%)<\/li><li><b>Hematologic:<\/b>Thrombophlebitis (2.4%)<\/li><li><b>Hepatic:<\/b>Conjugated hyperbilirubinemia (3.1% to 34.6%), Hyperbilirubinemia (0.9% to 25%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia, Myalgia<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction (less than 0.1%), Syncope (less than 0.1%), Ventricular fibrillation (less than 0.1%)<\/li><li><b>Endocrine metabolic:<\/b>Acidosis (less than 0.1%)<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage (less than 0.2%), Pancreatitis (less than 1%)<\/li><li><b>Hematologic:<\/b>Hemolytic anemia (less than 0.1%), Pancytopenia (less than 0.1%)<\/li><li><b>Hepatic:<\/b>Hepatitis (less than 0.1%)<\/li><li><b>Immunologic:<\/b>Anaphylaxis (less than 0.1%), Hypersensitivity reaction (less than 1%)<\/li><li><b>Musculoskeletal:<\/b>Generalized myasthenia (less than 1%)<\/li><li><b>Neurologic:<\/b>Cerebral hemorrhage (less than 0.1%), Cerebrovascular accident (less than 0.1%), Encephalopathy (less than 0.1%)<\/li><\/ul>"},{"id":"jtrgs6","title":"Drug Name Info","sub":{"0":{"id":"jtrgs6b17","title":"US Trade Names","mono":"Synercid<br\/>"},"2":{"id":"jtrgs6b19","title":"Class","mono":"<ul><li>Antibiotic<\/li><li>Streptogramin<\/li><\/ul>"},"3":{"id":"jtrgs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jtrgs6b21","title":"Generic Availability","mono":"No<br\/>"}}},{"id":"jtrgs7","title":"Mechanism Of Action","mono":"Systemic: Quinupristin and dalfopristin combination is bacteriostatic against Enterococcus faecium and bactericidal against strains of methicillin-susceptible and methicillin-resistant staphylococci. The site of action of quinupristin and dalfopristin combination is the bacterial ribosome. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. The combination of the two components acts synergistically and is more effective in vitro than each component alone. In vitro synergism of the major metabolites with the complimentary parent compound has been demonstrated.<br\/>"},{"id":"jtrgs8","title":"Pharmacokinetics","sub":{"1":{"id":"jtrgs8b24","title":"Distribution","mono":"<ul><li>Systemic: Quinupristin- Vd: 0.45 L\/kg<\/li><li>Dalfopristin- Vd: 0.24 L\/kg<\/li><\/ul>"},"2":{"id":"jtrgs8b25","title":"Metabolism","mono":"Systemic: Hepatic:  Active metabolites: glutathione and cysteine conjugated metabolites and dalfopristin<br\/>"},"3":{"id":"jtrgs8b26","title":"Excretion","mono":"<ul><li>Systemic: Quinupristin- Fecal: 75 to 77%; Renal: 15%<\/li><li>Dalfopristin- Renal: 19%<\/li><\/ul>"},"4":{"id":"jtrgs8b27","title":"Elimination Half Life","mono":"<ul><li>Systemic: Quinupristin- 0.85 h<\/li><li>Dalfopristin- 0.7 h<\/li><\/ul>"}}},{"id":"jtrgs9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>reconstitute vial with D5W or sterile water for injection and dilute within 30 minutes<\/li><li>dilute in 250 to 750 mL D5W (500 to 750 mL may decrease vein irritation); may be diluted in 100 mL D5W for central venous administration; do not dilute with saline (not compatible)<\/li><li>diluted solution stable 5 hours at room temperature or 54 hours under refrigeration; do not freeze the solution<\/li><li>infuse over 60 minutes<\/li><li>flush vein with D5W after peripheral administration to minimize venous irritation<\/li><li>flush line before and after administration with D5W; do not flush IV line with NS or heparin<\/li><\/ul>"},{"id":"jtrgs10","title":"Monitoring","mono":"<ul><li>fever<\/li><li>CBC<\/li><li>symptomatic improvement<\/li><li>bilirubin levels<\/li><\/ul>"},{"id":"jtrgs11","title":"How Supplied","mono":"<b>Synercid<\/b><br\/>Intravenous Powder for Solution: (Dalfopristin - Quinupristin) 350 MG-150 MG<br\/>"},{"id":"jtrgs12","title":"Toxicology","sub":[{"id":"jtrgs12b31","title":"Clinical Effects","mono":"<b>STREPTOGRAMINS<\/b><br\/>OVERDOSE: Based on limited data, overdoses of approximately 3 times the recommended dose of 7.5 mg\/kg have produced no clinical effects. Clinical effects may include dyspnea, vomiting, tremors and ataxia as observed in animal studies. ADVERSE EFFECTS: Adverse events related to oral or parenteral streptogramin use are mild to moderate and are most often related to gastrointestinal disturbances (nausea, vomiting, diarrhea, dyspepsia), central nervous system reactions (dizziness, insomnia,  anxiety, confusion), and arthralgia\/myalgia, which may be severe. Injection site reaction including edema and pain are relatively common and thrombophlebitis may develop in some patients. Rash and pruritus may occur. Hyperbilirubinemia has also been reported in some patients during therapy. Allergic reactions have been reported infrequently.<br\/>"},{"id":"jtrgs12b32","title":"Treatment","mono":"<b>STREPTOGRAMINS<\/b><br\/><ul><li>Decontamination: No data on overdose ingestions available. Activated charcoal may be indicated following a significant exposure.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Monitoring of patient: Monitor hepatic enzymes in symptomatic patients. Monitor fluid and electrolyte status in patients with significant vomiting.<\/li><li>Acute allergic reaction: Infrequent reports of hypersensitivity and allergic reaction have been reported with therapeutic use.<\/li><li>Hemodialysis: Based on the manufacturer, hemodialysis or peritoneal dialysis is NOT anticipated to be effective following a quinupristin\/dalfopristin overdose.<\/li><\/ul>"},{"id":"jtrgs12b33","title":"Range of Toxicity","mono":"<b>STREPTOGRAMINS<\/b><br\/>TOXICITY: There have been several reports of individuals receiving up to 3 times the recommended dose with no clinical events reported. Possible signs of acute overdose following quinupristin\/dalfopristin may include dyspnea, vomiting, tremors and ataxia, which is based on animals given doses of 50 mg\/kg. THERAPEUTIC: Adult: 7.5 mg\/kg IV every 8 hours; infused over 60 minutes. <br\/>"}]},{"id":"jtrgs13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause nausea and injection site inflammation, pain, and edema.<\/li><li>Patient should report jaundice, arthralgia, or myalgia.<\/li><li>Instruct patient to report severe diarrhea and consult healthcare professional prior to taking anti-diarrhea medicine.<\/li><\/ul>"}]}